Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection
- PMID: 15310993
- DOI: 10.1097/01.ju.0000134619.72675.8d
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection
Abstract
Purpose: The performance characteristics of percent free (f) prostate specific antigen (PSA) for differentiating between benign prostatic hyperplasia and prostate cancer were originally established using primarily sextant biopsy. We determined whether the addition of 6 laterally directed cores to the traditional sextant prostate biopsy affects the performance of percent fPSA.
Materials and methods: We retrospectively evaluated a cohort of 350 consecutive biopsies in men with negative digital rectal examinations and PSA between 4 and 10 ng/ml who underwent systematic 12 core biopsy (S12C) biopsy at Scott Department of Urology between March 1999 and January 2003. The effects of 6 additional, laterally directed biopsies on the sensitivity, specificity and area under the ROC curve for percent fPSA was evaluated in the 277 men in whom percent fPSA was measured.
Results: Cancers detected exclusively in the 6 laterally directed cores were associated with percent fPSA values similar to those in patients with a benign S12C biopsy. This resulted in a modest and yet predictable decrease in the sensitivity of percent fPSA at each biopsy threshold value without affecting specificity. There was a nonstatistically significant decrease in the area under the ROC curve with the addition of 6 laterally directed cores to sextant biopsy (medial sextant cores 0.66 vs S12C 0.60).
Conclusions: The 12 core biopsy strategies have a higher cancer detection rate than sextant biopsies and they are gaining widespread acceptance. The addition of 6 laterally directed cores to traditional sextant biopsy may result in a modest decrease in the sensitivity of percent fPSA at each selected biopsy threshold without affecting specificity.
Similar articles
-
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.J Urol. 2002 Aug;168(2):504-8. J Urol. 2002. PMID: 12131298
-
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.J Urol. 2003 Sep;170(3):723-6. doi: 10.1097/01.ju.0000086940.10392.93. J Urol. 2003. PMID: 12913682
-
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.J Urol. 2003 Nov;170(5):1787-91. doi: 10.1097/01.ju.0000092695.55705.dd. J Urol. 2003. PMID: 14532777 Clinical Trial.
-
Prostate biopsy: who, how and when. An update.Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Can J Urol. 2005. PMID: 15780165 Review.
-
The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.BJU Int. 2007 Sep;100(3):514-7. doi: 10.1111/j.1464-410X.2007.07000.x. Epub 2007 Jun 2. BJU Int. 2007. PMID: 17542987 Review.
Cited by
-
High-risk prostate cancer: value of multi-modality 3T MRI-guided biopsies after previous negative biopsies.Abdom Imaging. 2012 Oct;37(5):892-6. doi: 10.1007/s00261-011-9818-6. Abdom Imaging. 2012. PMID: 22038330 Free PMC article.
-
Ultrasound-guided three-dimensional needle steering in biological tissue with curved surfaces.Med Eng Phys. 2015 Jan;37(1):145-50. doi: 10.1016/j.medengphy.2014.10.005. Epub 2014 Oct 31. Med Eng Phys. 2015. PMID: 25455165 Free PMC article.
-
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?J Urol. 2014 Oct;192(4):1094-9. doi: 10.1016/j.juro.2014.04.015. Epub 2014 Apr 18. J Urol. 2014. PMID: 24747090 Free PMC article. Clinical Trial.
-
Molecular diagnosis of prostate cancer.Curr Urol Rep. 2004 Jun;5(3):203-11. doi: 10.1007/s11934-004-0038-2. Curr Urol Rep. 2004. PMID: 15161569 Review.
-
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.Rev Urol. 2004 Spring;6(2):58-72. Rev Urol. 2004. PMID: 16985579 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous